Full Press Release Details
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
NEW YORK (BUSINESS WIRE) January 22, 2019 UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing
treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public
offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the public offering price, less
the underwriting discounts and commissions. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All ordinary
shares to be sold in this offering will be offered by the company.
Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint
book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering.
A shelf registration statement relating to
the ordinary shares was previously filed with the Securities and Exchange Commission (the SEC ) and declared effective on October 26, 2018. A preliminary prospectus supplement and accompanying prospectus relating to the offering will
be filed with the SEC and will be available on the SEC s website at http://www.sec.gov. Copies of the preliminary prospectus supplement (when available) and accompanying prospectus may be obtained by contacting:
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made
only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced
non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel , a proprietary sustained release,
hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. UroGen s lead product candidates, UGN-101 and UGN-102, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial
carcinoma and bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect
to the timing and size of the proposed offering and the anticipated use of proceeds, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: market conditions, the timing and success of
clinical trials and potential complications thereof; the ability to obtain and maintain regulatory approval; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen Pharma s product
candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis- -vis alternative therapies; and UroGen
Pharma s ability to attract or retain key management, members of the board of directors and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen
Pharma s Form 20-F filed with the SEC on March 15, 2018, its Current Report on Form 8-K filed with the SEC on January 22, 2019, and in the preliminary prospectus supplement and
accompanying prospectus relating to the offering to be filed with the SEC, and other filings that UroGen Pharma makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such
forward-looking statements may not occur, and UroGen Pharma s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are
based on information available to UroGen Pharma as of the date of this release.
Director, Corporate Communications &